Details
Stereochemistry | MIXED |
Molecular Formula | C20H37O7S.Na |
Molecular Weight | 444.558 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 0 / 3 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].CCCCC(CC)COC(=O)CC(C(=O)OCC(CC)CCCC)S([O-])(=O)=O
InChI
InChIKey=APSBXTVYXVQYAB-UHFFFAOYSA-M
InChI=1S/C20H38O7S.Na/c1-5-9-11-16(7-3)14-26-19(21)13-18(28(23,24)25)20(22)27-15-17(8-4)12-10-6-2;/h16-18H,5-15H2,1-4H3,(H,23,24,25);/q;+1/p-1
Molecular Formula | C20H37O7S |
Molecular Weight | 421.569 |
Charge | -1 |
Count |
|
Stereochemistry | MIXED |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 3 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Molecular Formula | Na |
Molecular Weight | 22.9898 |
Charge | 1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Docusate, also known as docusate salts or dioctyl sulfosuccinate, prevents/relieves dry hard stool and thus is used to treat constipation. Results usually occurs 1 to 3 days after the first dose. In North America, docusate and a stimulant laxative such as sennosides are commonly used in bowel treatment protocols associated with institutionalized elderly and oncology treatments. A paucity of evidence is available to support the use of the stool softener docusate yet it continues to be prescribed in everyday clinical practice for the aforementioned populations. While the actual cost of docusate is low, additional costs associated with its administration (i.e. nursing time) and its widespread use can be significant. Docusate is absorbed into the bloodstream and excreted via the gallbladder after undergoing extensive metabolism. The effect of docusate may not necessarily be all due to its surfactant properties. Perfusion studies suggest that docusate inhibits fluid absorption or stimulates secretion in the portion of the small intestine known as the jejunum
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Hydration and protein folding in water and in reverse micelles: compressibility and volume changes. | 2001 Jun |
|
Microstructure determination of AOT + phenol organogels utilizing small-angle X-ray scattering and atomic force microscopy. | 2001 Mar 14 |
|
Separation and simultaneous determination of water-soluble and fat-soluble vitamins by electrokinetic capillary chromatography. | 2002 Apr 12 |
|
[The lipase/lipoxygenase bienzyme system in AOT reversed micelles in octane]. | 2002 Jan-Feb |
|
Spectrophotometric investigation of the binding of vitamin E to water-containing reversed micelles. | 2002 Mar 2 |
|
Effect of di-2-ethylhexyl sodium sulfosuccinate reversed micelles on the iron-tetrasulfonatophthalocyanine-catalyzed fluorogenic oxidation reaction of L-tyrosine with hydrogen peroxide. | 2002 May |
|
Surfactant-mediated capillary electrochromatography with octadecyl-silica- packed capillary columns for the separation of nonpolar compounds. Case of pyrethroid insecticides. | 2002 May |
|
Kinetic behavior of Desulfovibrio gigas aldehyde oxidoreductase encapsulated in reverse micelles. | 2003 Aug 15 |
|
Extraction of immunoglobulin-G from colostral whey by reverse micelles. | 2003 May |
|
Effect of reverse micelles on the Rose Bengal-sensitized photo-oxidation of 1- and 2-hydroxynaphthalenes. | 2004 |
|
Characterization and application of sodium di(2-ethylhexyl) sulfosuccinate and sodium di(2-ethylhexyl) phosphate surfactants as pseudostationary phases in micellar electrokinetic chromatography. | 2004 Dec 17 |
|
Selective precipitation and recovery of xylanase using surfactant and organic solvent. | 2004 Jun 20 |
|
Micro-Raman investigations of myelins in aerosol-OT/water system. | 2004 Jun 8 |
|
Effect of the addition of water-soluble polymers on the interfacial properties of aerosol OT vesicles. | 2004 Oct 15 |
|
Transition from micelle to vesicle in aqueous mixtures of anionic/zwitterionic surfactants studied by fluorescence, conductivity, and turbidity methods. | 2005 Apr 15 |
|
Comparative studies on the micellization of sodium bis(4-phenylbutyl) sulfosuccinate and sodium bis(2-ethylhexyl) sulfosuccinate and their interaction with hydrophobically modified poly(acrylamide). | 2005 Apr 26 |
|
Dynamics of water confined on a nanometer length scale in reverse micelles: ultrafast infrared vibrational echo spectroscopy. | 2005 Feb 11 |
|
Monolayer of aerosol-OT surfactants adsorbed at the air/water interface: an atomistic computer simulation study. | 2005 Jan 13 |
|
Investigation of micelle formation by fluorescence correlation spectroscopy. | 2005 Jul 14 |
|
Recycling nanoparticles stabilized in water-in-CO2 microemulsions for catalytic hydrogenations. | 2005 Mar 1 |
|
On the temperature percolation in a w/o microemulsion in the presence of organic derivatives of chalcogens. | 2005 May 19 |
|
Efficient gene transfection using chitosan-alginate core-shell nanoparticles. | 2006 |
|
Incorporation of substituted acrylamides to the lamellar mesophase of Aerosol OT. | 2006 Jul 1 |
|
Electrochemical extraction of proteins by reverse micelle formation. | 2006 Jun 20 |
|
Tuning the cooperativity of the helix-coil transition by aqueous reverse micelles. | 2006 Jun 22 |
|
Photodetachment of ferrocyanide in reverse micelles. | 2006 May 18 |
|
Study of confined 5-aza[5]helicene in ytterbium(III) bis(2-ethylhexyl) sulfosuccinate reversed micelles. | 2007 Apr 26 |
|
Compartmentalization of reactants in different regions of sodium 1,4-bis(2-ethylhexyl)sulfosuccinate/heptane/water reverse micelles and its influence on bimolecular electron-transfer kinetics. | 2007 Aug 2 |
|
Ultrafast energy transfer in water-AOT reverse micelles. | 2007 Dec 27 |
|
Dye-sensitized solar cells based on nanocrystalline titania electrodes made at various sintering temperatures. | 2007 Feb |
|
Iron dissolution in aqueous AOT solution. | 2007 Feb 15 |
|
The dispersion-stability diagram of boehmite nanoparticles in aqueous AOT solutions. | 2007 Feb 15 |
|
Comparative study of the photophysical behavior of fisetin in homogeneous media and in anionic and cationic reverse micelles media. | 2007 May-Jun |
|
Improvement in extraction and catalytic activity of Mucor javanicus lipase by modification of AOT reverse micelle. | 2007 Nov |
|
Site-specific hydration status of an amphipathic peptide in AOT reverse micelles. | 2007 Oct 23 |
|
The effect of changing the microstructure of a microemulsion on chemical reactivity. | 2007 Sep 11 |
|
On the possibility that cyclodextrins' chiral cavities can be available on AOT n-heptane reverse micelles. A UV-visible and induced circular dichroism study. | 2007 Sep 13 |
|
P450cam biocatalysis in surfactant-stabilized two-phase emulsions. | 2008 Apr 15 |
|
Molecular dynamics simulations of AOT-water/formamide reverse micelles: structural and dynamical properties. | 2008 Dec 28 |
|
Optical sensor of anionic surfactants using solid-phase extraction with a lactone-form rhodamine B membrane. | 2008 Jun |
|
Fluorescence anisotropy of ionic probes in AOT reverse micelles: influence of water droplet size and electrostatic interactions on probe dynamics. | 2008 Jun 19 |
|
Fine control over the morphology and structure of mesoporous silica nanomaterials by a dual-templating approach. | 2008 Oct 7 |
|
Characterization of multifunctional reverse micelles' interfaces using hemicyanines as molecular probes. II: Effect of the surfactant. | 2009 May 14 |
|
Study of the factors affecting the extraction of soybean protein by reverse micelles. | 2010 Feb |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/dosage/docusate.html
Usual Adult Dose for Constipation:
Oral: 50 to 400 mg (using any of the salt forms) orally administered in 1 to 4 equally divided doses each day.
Rectal: 200 to 283 mg rectally administered as an enema once or twice. Alternative: 50 to 100 mg (docusate sodium liquid) added to a retention or flushing enema once a day.
Usual Pediatric Dose for Constipation:
Oral: less than 3 years: 10 to 40 mg (docusate sodium) orally divided in 1 to 4 doses. 3 to 6 years: 20 to 60 mg (docusate sodium) orally divided in 1 to 4 doses. 6 to 12 years: 40 to 150 mg (docusate sodium) orally divided in 1 to 4 doses. greater than 12 years: 50 to 400 mg (using any of the salt forms) orally administered in 1 to 4 equally divided doses each day.
Rectal: 3 to 18 years: 50 to 100 mg (docusate sodium liquid) added to a retention or flushing enema once a day. Alternative: 200 to 283 mg rectally administered as an enema once daily as needed for constipation.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11530185
It was evaluated the efficacy and toxicity of docusate against herpes simplex viruses (HSV). Docusate was effective in vitro against wild type and drug-resistant strains of HSV type 1 and 2 with EC(90-100) (effective concentration giving 90-100% virus yield reduction) of approximately 0.005% (w/v). The cytotoxicity profiles of docusate were time- and dose-dependent and thus associated with the frequency of use. Kinetics of inactivation examined by pre-mixing virus and drug in a time-course experiment demonstrated that docusate could reach its EC(90-100) within 30 min.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:01:22 GMT 2023
by
admin
on
Fri Dec 15 15:01:22 GMT 2023
|
Record UNII |
F05Q2T2JA0
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
A06AG10
Created by
admin on Fri Dec 15 15:01:22 GMT 2023 , Edited by admin on Fri Dec 15 15:01:22 GMT 2023
|
||
|
CODEX ALIMENTARIUS (GSFA) |
INS-480
Created by
admin on Fri Dec 15 15:01:22 GMT 2023 , Edited by admin on Fri Dec 15 15:01:22 GMT 2023
|
||
|
CFR |
21 CFR 176.170
Created by
admin on Fri Dec 15 15:01:22 GMT 2023 , Edited by admin on Fri Dec 15 15:01:22 GMT 2023
|
||
|
WHO-VATC |
QA06AG10
Created by
admin on Fri Dec 15 15:01:22 GMT 2023 , Edited by admin on Fri Dec 15 15:01:22 GMT 2023
|
||
|
CFR |
21 CFR 172.520
Created by
admin on Fri Dec 15 15:01:22 GMT 2023 , Edited by admin on Fri Dec 15 15:01:22 GMT 2023
|
||
|
JECFA EVALUATION |
INS-480
Created by
admin on Fri Dec 15 15:01:22 GMT 2023 , Edited by admin on Fri Dec 15 15:01:22 GMT 2023
|
||
|
CFR |
21 CFR 172.810
Created by
admin on Fri Dec 15 15:01:22 GMT 2023 , Edited by admin on Fri Dec 15 15:01:22 GMT 2023
|
||
|
CFR |
21 CFR 175.320
Created by
admin on Fri Dec 15 15:01:22 GMT 2023 , Edited by admin on Fri Dec 15 15:01:22 GMT 2023
|
||
|
WHO-VATC |
QA06AA02
Created by
admin on Fri Dec 15 15:01:22 GMT 2023 , Edited by admin on Fri Dec 15 15:01:22 GMT 2023
|
||
|
WHO-ATC |
A06AA02
Created by
admin on Fri Dec 15 15:01:22 GMT 2023 , Edited by admin on Fri Dec 15 15:01:22 GMT 2023
|
||
|
NCI_THESAURUS |
C29699
Created by
admin on Fri Dec 15 15:01:22 GMT 2023 , Edited by admin on Fri Dec 15 15:01:22 GMT 2023
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
8.4
Created by
admin on Fri Dec 15 15:01:22 GMT 2023 , Edited by admin on Fri Dec 15 15:01:22 GMT 2023
|
||
|
DSLD |
3169 (Number of products:31)
Created by
admin on Fri Dec 15 15:01:22 GMT 2023 , Edited by admin on Fri Dec 15 15:01:22 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
6
Created by
admin on Fri Dec 15 15:01:22 GMT 2023 , Edited by admin on Fri Dec 15 15:01:22 GMT 2023
|
PRIMARY | |||
|
531
Created by
admin on Fri Dec 15 15:01:22 GMT 2023 , Edited by admin on Fri Dec 15 15:01:22 GMT 2023
|
PRIMARY | |||
|
C460182
Created by
admin on Fri Dec 15 15:01:22 GMT 2023 , Edited by admin on Fri Dec 15 15:01:22 GMT 2023
|
PRIMARY | |||
|
m4716
Created by
admin on Fri Dec 15 15:01:22 GMT 2023 , Edited by admin on Fri Dec 15 15:01:22 GMT 2023
|
PRIMARY | Merck Index | ||
|
23673837
Created by
admin on Fri Dec 15 15:01:22 GMT 2023 , Edited by admin on Fri Dec 15 15:01:22 GMT 2023
|
PRIMARY | |||
|
CHEMBL1477036
Created by
admin on Fri Dec 15 15:01:22 GMT 2023 , Edited by admin on Fri Dec 15 15:01:22 GMT 2023
|
PRIMARY | |||
|
1224802
Created by
admin on Fri Dec 15 15:01:22 GMT 2023 , Edited by admin on Fri Dec 15 15:01:22 GMT 2023
|
PRIMARY | |||
|
577-11-7
Created by
admin on Fri Dec 15 15:01:22 GMT 2023 , Edited by admin on Fri Dec 15 15:01:22 GMT 2023
|
PRIMARY | |||
|
C29000
Created by
admin on Fri Dec 15 15:01:22 GMT 2023 , Edited by admin on Fri Dec 15 15:01:22 GMT 2023
|
PRIMARY | |||
|
F05Q2T2JA0
Created by
admin on Fri Dec 15 15:01:22 GMT 2023 , Edited by admin on Fri Dec 15 15:01:22 GMT 2023
|
PRIMARY | |||
|
F05Q2T2JA0
Created by
admin on Fri Dec 15 15:01:22 GMT 2023 , Edited by admin on Fri Dec 15 15:01:22 GMT 2023
|
PRIMARY | |||
|
71722
Created by
admin on Fri Dec 15 15:01:22 GMT 2023 , Edited by admin on Fri Dec 15 15:01:22 GMT 2023
|
PRIMARY | RxNorm | ||
|
941
Created by
admin on Fri Dec 15 15:01:22 GMT 2023 , Edited by admin on Fri Dec 15 15:01:22 GMT 2023
|
PRIMARY | |||
|
DTXSID8022959
Created by
admin on Fri Dec 15 15:01:22 GMT 2023 , Edited by admin on Fri Dec 15 15:01:22 GMT 2023
|
PRIMARY | |||
|
209-406-4
Created by
admin on Fri Dec 15 15:01:22 GMT 2023 , Edited by admin on Fri Dec 15 15:01:22 GMT 2023
|
PRIMARY | |||
|
3065
Created by
admin on Fri Dec 15 15:01:22 GMT 2023 , Edited by admin on Fri Dec 15 15:01:22 GMT 2023
|
PRIMARY | |||
|
133817
Created by
admin on Fri Dec 15 15:01:22 GMT 2023 , Edited by admin on Fri Dec 15 15:01:22 GMT 2023
|
PRIMARY | |||
|
SUB06348MIG
Created by
admin on Fri Dec 15 15:01:22 GMT 2023 , Edited by admin on Fri Dec 15 15:01:22 GMT 2023
|
PRIMARY | |||
|
DBSALT001500
Created by
admin on Fri Dec 15 15:01:22 GMT 2023 , Edited by admin on Fri Dec 15 15:01:22 GMT 2023
|
PRIMARY | |||
|
DIOCTYL SODIUM SULFOSUCCINATE
Created by
admin on Fri Dec 15 15:01:22 GMT 2023 , Edited by admin on Fri Dec 15 15:01:22 GMT 2023
|
PRIMARY | |||
|
760404
Created by
admin on Fri Dec 15 15:01:22 GMT 2023 , Edited by admin on Fri Dec 15 15:01:22 GMT 2023
|
PRIMARY | |||
|
100000092012
Created by
admin on Fri Dec 15 15:01:22 GMT 2023 , Edited by admin on Fri Dec 15 15:01:22 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |